Teva launches generic EpiPen in the U.S.

Mylan's EpiPen
Teva received an FDA approval of its generic version in August, following delays of more than two years. (Greg Friese/Flickr)

Teva has begun a limited U.S. commercial launch of its generic version of Mylan’s EpiPen epinephrine autoinjector, with the 0.3-mg version being made available to the public at a wholesale acquisition cost of $300, the same price as Mylan’s own authorized generic launched almost two years ago.

Additional supplies of Teva’s generic, as well as its version of the EpiPen Jr, at 0.15 mg, are expected to be available in 2019, the company said.

Teva received an FDA approval of its generic version in August, following delays of more than two years.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The approval came while EpiPens were in short supply, with shortages continuing after FDA investigators found problems last year at a Meridian Medical Technologies plant, a Pfizer subsidiary that manufactures the autoinjectors for Mylan.

RELATED: With EpiPen competitors bearing down, can Mylan maintain its lead?

In May, the agency added the EpiPen and injectors from Impax Laboratories to its drug shortages list, after Mylan recalled 80,000 possibly faulty injectors shipped outside the U.S.

The FDA has previously approved competitors to Mylan’s EpiPen under new drug applications, such as Amedra Pharmaceuticals’ Adrenaclick and Kaleo’s Auvi-Q.

In addition, Novartis’ Sandoz unit recently acquired the U.S. rights to Symjepi, a prefilled epinephrine syringe from Adamis Pharmaceuticals.

Novartis has decided to jump onto EpiPen’s playing field. The Swiss drugmaker’s Sandoz unit snapped up U.S. rights to Symjepi, the Adamis Pharmaceuticals prefilled epinephrine syringe, positioned as a low-cost alternative to autoinjectors.

Suggested Articles

Bio-Rad Laboratories received FDA clearance for two digital PCR products designed to monitor CML patients’ molecular responses to treatment.

Neuspera Medical raised a total of $26 million through the second tranche of a series B round, to fund clinical testing programs for its implants.

Voyager stands to receive up to $728 million in milestones for each compound AbbVie chooses to advance beyond phase 1.